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Abstract
Background: Alcohol dehydrogenase 1C (ADH1C) is the key enzyme catalyze oxidation of alcohol to acetaldehyde, which
plays vital roles in the etiology of various cancer. To date, studies investigated the association between a functional
polymorphism in ADH1C, Ile350Val (rs698), and risk of cancer have shown inclusive results.
Methods: A meta-analysis based on 35 case-control studies was performed to address this issue. Odds ratios (OR) with 95%
confidence intervals (CIs) were used to assess the association. The statistical heterogeneity across studies was examined
with x2-based Q-test.
Results: Overall, no significant associations between ADH1C Ile350Val polymorphism and cancer risk were observed in any
genetic models (P.0.05). In the stratified analyses, there was a significantly increased cancer risk among African (Val/Val vs.
Ile/Ile OR =2.19, 95% CI =1.2923.73, Pheterogeneity =0.989; Ile/Val + Val/Val vs. Ile/Ile: OR =1.79, 95%CI =1.1822.71,
Pheterogeneity =0.761; Val/Val vs. Ile/Val + Ile/Ile: OR =1.92, 95% CI =1.1623.17, Pheterogeneity =0.981) and Asian (Ile/Val vs.
Ile/Ile: OR =1.58, 95% CI =1.3221.90, Pheterogeneity =0.375; Val/Val vs. Ile/Ile: OR =3.84, 95% CI =1.7428.49, Pheterogeneity
=0.160; Ile/Val + Val/Val vs. Ile/Ile: OR =1.65, 95% CI =1.3821.96, Pheterogeneity =0.330; Val/Val vs. Ile/Val + Ile/Ile: OR =3.54,
95% CI =1.6227.75, Pheterogeneity =0.154) studies.
Conclusions: The results indicate that ADH1C Ile350Val polymorphism may contribute to cancer risk among Africans and
Asians. Additional comprehensive system analyses are required to validate this association combined with other related
polymorphisms.
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Introduction
There has been convincing evidence that alcohol ingestion is
carcinogenic to humans and causally related to liver, colorectal,
breast and upper aerodigestive tract (UADT) cancers [1].
Although multiple mechanisms are involved in alcohol-mediated
carcinogenesis, it has been shown that acetaldehyde (AA), the
oxidative product of ethanol (commonly called alcohol), rather
than alcohol itself is the principal carcinogenic material in alcohol
metabolism [2]. AA interferes at many sites with DNA synthesis
and repair and consequently has direct mutagenic and carcino-
genic effects [3]. The key enzyme responsible for oxidation of
ethanol to AA is alcohol dehydrogenase (ADH) [4]. Human ADH
family is a well-defined system of enzymes which play important
role in detoxification of alcohols and are categorized into several
classes based on differences in substrate specificity, sensitivity to
inhibitors, localization, electrophoretic migration and immuno-
logical properties [5]. In addition to the first-pass ethanol
metabolism, ADH has shown various functions including activity
towards hydroxysteroids, detoxification of endogenous and exog-
enous formaldehyde, retinoid transformation, etc. [6,7,8]. The
differences of the activities of total ADH and ADH isoenzymes
between cancer and healthy tissue have been demonstrated [4]. As
production rate of AA is mainly modulated by ADH, it is rational
that ADH activity variation may have effects on the level of AA in
vivo and be one of the factors intensifying carcinogenesis.
There are seven genes that encode the seven known isozymes of
human ADH. According to structural characteristics, the seven
isozymes are categorized into five different classes, among which
Class I isozymes account for most of the alcohol metabolism [9].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37227The three class I genes, ADH1A, ADH1B, and ADH1C (formerly
known as ADH1, ADH2 and ADH3) are very closely related; they
encode alpha (a), beta (b) and gamma (c) subunits, respectively
[10]. Functional variants (i.e., single nucleotide polymorphisms,
SNPs) arousing wide concern exist in two of three genes encoding
ADH enzymes (i.e., the ADH1B and ADH1C genes) [11]. The
polymorphic sites for ADH1B are Arg48His in exon 3 (rs1229984)
and Arg370Cys in exon 9 (rs2066702) and for ADH1C are
Arg272Gln (rs1693482) and Ile350Val (rs698) [10]. The
ADH1B*1 allele is a name for the reference allele encoding b1
subunit which has arginine (Arg) at positions 48 and 370.
ADH1B*2 (b2) refers to a variant allele defined by histidine (His)
at position 48 while ADH1B*3 encoding b3 subunit that has
cysteine (Cys) at position 370 [10]. For polymorphisms in ADH1C,
272Arg and 350Ile carriers have the ADH1C*1 allele, whereas
272 Gln and 350 Val carriers have the ADH1C*2 allele [12]. It is
worth noting that significant linkage disequilibrium has been
detected between the ADH1B and ADH1C polymorphisms as well
as the two variants in ADH1C [13,14]. These functional variants
result in the production of enzymes with different kinetic
properties [10,15] and subsequently the generation of different
quantities of AA. For example, individuals with ADH1C*1 allele
have an ethanol oxidizing capacity 2.5-times higher when
compared to ADH1C*2 allele [12]. Thus, not only the amount
of alcohol is determinant for organ injury, but also the genetic
factors may modulate and determine carcinogenesis.
An increasing number of studies have investigated the
association between ADH polymorphisms and cancer risk in
human. Among them, studies of ADH1C Ile350Val variant
accounted for more than others. Most of the ADH1C studies
focused on head and neck cancer (HNC) development, and to a
less extent on the cancers of breast, colorectum, etc. Although
genotype frequency of Ile350Val polymorphism varies among
different populations [16], evidences supporting the association
between this genetic variant and risk of cancer have arisen from
studies of different ethnic background [17,18,19]. Recently,
Chang et al. conducted a meta-analysis to assess the association
between ADH1B and ADH1C polymorphisms and risk of HNC
[20], and they found a reduced risk for HNC associated with
ADH1B*2 and ADH1C*1 alleles. However, as the studies on
ADH1C polymorphism and different cancer risk have shown
contradictory and inconclusive results, a pooled analysis of all
studies on ADH1C and cancer risk is needed.
Here, we performed a meta-analysis on 35 eligible case-control
studies to estimate the overall cancer risk and ADH1C polymor-
phisms. Because polymorphisms of Arg272Gln and Ile350Val
were in strong linkage disequilibrium and both of them can be
used to distinguish ADH1C*1 and ADH1C*2 alleles, we focused on
the most commonly studied polymorphism Ile350Val.
Materials and Methods
Identification and Eligibility of Relevant Studies
PubMed and EMBASE were searched for all relevant reports
(the last search update was July 18, 2011), using the search terms
‘‘ADH1C’’ or ‘‘ADH3’’, ‘‘polymorphism’’ and ‘‘cancer’’. The
search was limited to English language papers. In addition, studies
were identified by a manual search of the references of original
studies. Of the articles with the overlapping data, we only selected
the publication with the most extensive information. For inclusion
in the meta-analysis, the identified articles had to meet the
following criteria: (a) there were information on the evaluation of
the ADH1C Ile350Val polymorphism and cancer risk, (b) used a
case–control design, and (c) contained complete information about
all genotype frequency. The exclusion criteria were as follows: (a)
not for cancer research, (b) review articles, (c) reports without
usable data and (d) duplicate publications.
Data Extraction
Two authors (Y Xue and M Wang) extracted data from all
eligible publications independently and reached a consensus on all
the items. For each study, the following characteristics were
considered: the first author’s last name, year of publication,
country of origin, ethnicity, cancer type, source of control groups
(population- or hospital-based controls) and numbers of genotyped
cases and controls. Different ethnic descents were categorized as
African, Asian, European, or Mixed (composed of different ethnic
groups). Cancers of oral cavity, oropharynx, hypopharynx, larynx,
esophagus and stomach were defined as upper aerodigestive tract
(UADT) cancers [21,22]. For studies including subjects of different
ethnic groups or cancer types, data were extracted separately for
each ethnic group or cancer type whenever possible.
Statistical Analysis
The strength of the association between the ADH1C Ile350Val
polymorphisms and cancer risk was measured by odds ratios (ORs)
with their 95% confidence intervals (CIs). The statistical signifi-
cance of the summary OR was determined with the Z-test. We
first explored the risks of the Ile/Val and Val/Val genotypes on
cancer, compared with the wild-type Ile/Ile homozygote, and then
evaluated the risks of Ile/Val + Val/Val versus Ile/Ile and Val/
Val versus Ile/Val + Ile/Ile on cancer, assuming dominant and
recessive effects of the variant Val allele, respectively. Stratified
analyses were also performed by cancer types (if one cancer type
contained less than three individual studies, it was classified as
other cancers group), ethnicity, source of controls and sample size
(subjects .500 in both case and control groups or not).
In consideration of the possibility of heterogeneity across the
studies, a statistical test for heterogeneity was performed by a x
2-
based Q-test. A P-value greater than 0.10 for the Q-test indicated
lack of heterogeneity among the studies, and then the fixed-effects
model (the Mantel–Haenszel method) was used to calculate the
summary OR estimate of each study. Otherwise, the random-
effects model (DerSimonian and Laird method) was used.
Sensitivity analyses were performed to assess the stability of the
results, namely, a single study in the meta-analysis was deleted
each time to reflect the influence of the individual data set to the
pooled OR. The presence of publication bias indicates that non-
significant or negative findings remain unpublished. We used
Funnel plots and Egger’s linear regression test to provide diagnosis
of the potential publication bias. All statistical analyses were
performed with the Stata software (version 8.2; StataCorp LP,
College Station, TX, USA), using two-sided P-values.
Results
Characteristics of Studies
There were 35 studies retrieved on the basis of the search
criteria for cancer susceptibility associated with ADH1C Ile350Val
polymorphisms (Fig. 1). Totally, 19,154 cases and 26,519 controls
were included in the meta-analysis. Study characteristics are
summarized in Table 1. Among the 35 case–control studies, there
were 5 studies of Asians, 19 studies of Europeans and 8 studies of
mixed descendents. Besides, 3 studies included more than one
ethnic group [14,23,24]. Thus, in total, 2 African groups, 5 Asian
groups, 21 European groups and 10 groups of mixed descendents
were recruited in our analyses. Controls were mainly matched on
sex and age, of which 14 were population based
ADH1C Polymorphism and Cancer Risk
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based [17,18,19,23,37,38,39,40,41,42,43,44,45,46,47,48] and 5
studies was conducted on both population-based and hospital-
based control group [14,22,49,50,51]. Furthermore, 7 studies were
conducted with subjects .500 in both case and control groups
[14,26,28,29,34,38,51]. There were 4 studies of breast cancer, 25
of UADT cancer, 3 of colorectal and 3 of other cancers. Among
the 25 UADT cancer studies, Homann et al. investigated the
ADH1C polymorphism and cancer risk in both UADT cancer and
hepatocellular cancer groups [50]. Thus, number of studies of
‘‘other cancers’’ was 4. Cancers were confirmed histologically or
pathologically in most studies. The distribution of genotypes in the
controls of all studies was consistent with Hardy–Weinberg
equilibrium (HWE) except for 10 studies, 9 of which did not
mention the HWE test [24,31,33,36,37,41,44,48,49] and in one
study allele distributions were not in HWE for a part of controls
[43].
Quantitative Synthesis
There was a wide variation of the 350 Val allele frequency
among the controls across different ethnicities. The 350 Val
allele frequency was the lowest in Asian populations and was the
highest in European populations (0.05, 95% CI =0.0320.09, vs.
0.40, 95% CI =0.3620.44). In African and mixed populations,
the allele frequency was 0.29 (95% CI =21.1521.58) and 0.35
(95% CI =0.2720.39), respectively. The difference among the
four population groups was statistically significant (P,0.001). In
the overall analyses, we did not observe any significant
associations between the ADH1C Ile350Val polymorphism and
cancer risk in all the genetic models (Table 2, Fig. 2 of dominant
model). Because population admixture may be a potential cause
of inconsistent results [52], we excluded studies with mixed
populations to further evaluate the overall effect of ADH1C
Ile350Val polymorphism and we still didn’t find any significant
associations (data not shown). However, in the stratified analysis
by ethnicity, significant increased risks were found for African
populations (homozygote comparison: OR =2.19, 95% CI
=1.2923.73, Pheterogeneity =0.989; dominant model: OR =1.79,
95% CI =1.1822.71, Pheterogeneity =0.761; recessive model:
OR =1.92, 95% CI =1.1623.17, Pheterogeneity =0.981) and
Asian populations (heterozygote comparison: OR =1.58, 95%
CI =1.3221.90, Pheterogeneity =0.375; homozygote comparison:
OR =3.84, 95% CI =1.7428.49, Pheterogeneity =0.160;
dominant model: OR =1.65, 95% CI =1.3821.96, Pheterogeneity
=0.330; recessive model: OR =3.54, 95% CI =1.6227.75,
Pheterogeneity =0.154) (Table 2, Fig. 3 of dominant model ). When
Figure 1. Studies identified with criteria for inclusion and exclusion.
doi:10.1371/journal.pone.0037227.g001
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individuals with the Val/Val genotypes had a 0.58-fold lower
breast cancer risk compared with the Ile/Ile genotype (OR
=0.58, 95% CI =0.3421.00, Pheterogeneity =0.001, Table 2) (P
=0.049, data not shown). We did not observe any significant
associations among UADT cancer, colorectal cancer and other
cancers (Table 2). However, cancer-specific analysis excluding
studies with mixed populations indicated that a moderate
increased risk of UADT cancer was associated with variant Val
allele in dominant model (OR =1.17, 95% CI =1.0121.36,
Pheterogeneity ,0.001, data not shown). Furthermore, when we
conducted stratified analyses according to source of controls and
sample size, no significant associations were found in any genetic
models (Table 2).
Test for Heterogeneity
There was significant heterogeneity for heterozygote compar-
ison (Ile/Val versus Ile/Ile: Pheterogeneity ,0.001), homozygote
comparison (Val/Val versus Ile/Ile: Pheterogeneity ,0.001),
dominant model comparison (Val/Val + Ile/Val versus Ile/
Ile: Pheterogeneity ,0.001) and recessive model comparison (Val/
Val versus Ile/Val + Ile/Ile: Pheterogeneity ,0.001). Then, we
assessed the source of heterogeneity for heterozygote compar-
ison (Ile/Val versus Ile/Ile) by ethnicity, cancer type, source of
Table 1. Characteristics of studies included in the meta-analysis.
First author Year Country Ethnicity Cancer types
Source of
controls Sample size
Case Control
Coutelle 1997 France European UADT HB 39 37
Harty 1997 Puerto Rico Mixed UADT PB 146 146
Freudenheim 1999 USA European Breast PB 315 356
Bouchardy 2000 France European UADT HB 244 167
Chao 2000 China Asian UADT HB 88 434
Olshan 2001 USA European and African UADT HB 173 194
Sturgis 2001 USA European UADT HB 229 575
Schwartz 2001 USA European UADT PB 333 541
Dijk 2001 Netherlands European Bladder HB 115 131
Zavras 2002 Greece European UADT HB 93 99
Yokoyama 2002 Japan Asian UADT PB 234 634
Freudenheim 2003 USA Mixed Lung PB 113 212
Nishimoto 2004 Brazil Mixed UADT Combined 141 134
Coutelle 2004 German European Breast HB 117 111
Peters 2005 USA European UADT PB 521 599
Wang 2005 USA European UADT HB 348 330
Homann 2006. German European UADT and Hepatocellular Combined 293 729
Logt 2006 Netherlands European Colorectal PB 320 385
Terry 2006 USA Mixed Breast PB 1047 1101
Terry 2007 USA Mixed UADT PB 197 160
Zhang 2007 Poland European UADT PB 297 425
Yin 2007 Japan Asian Colorectal PB 685 777
Visvanathan 2007 USA European Breast PB 303 312
Asakage 2007 Japan Asian UADT HB 96 642
Curtin 2007 USA Mixed Colorectal PB 915 1969
Solomon 2008 India Mixed UADT HB 126 100
Hashibe 2008 Multi-Countries European and Mixed UADT Combined 3393 4851
Li 2008 South Africa African and Mixed UADT PB 237 268
Oze 2009 Japan Asian UADT HB 585 1170
Garcia 2010 Brazil Mixed UADT HB 207 244
Duchonova 2010 Czech European Pancreatic HB 235 264
Kortunay 2010 Turkey European UADT HB 50 100
Soucek 2010 Slav European UADT HB 121 121
Brocic 2011 Serbia European UADT Combined 123 177
Mckay 2011 Multi-Countries European UADT Combined 6675 8024
UADT, upper aerodigestive tract; HB, hospital based; PB, population based; Combined, studies conducted on both population-based and hospital-based control group.
doi:10.1371/journal.pone.0037227.t001
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2=28.01, df
=3, P,0.001) and cancer type (x
2=8.39, df =3, P =0.039)
but not source of controls (x
2=3.54, df =2, P =0.171) or
sample size (x
2=0.52, df =1, P =0.470) were found to
contribute to substantial heterogeneity.
Sensitivity Analyses
Sensitivity analyses indicated that two independent studies by
Hashibe et al. in 2008 and Homann et al. in 2006 were the main
origin of heterogeneity [14,50]. In addition, no other single study
influenced the pooled OR qualitatively, as indicated by sensitivity
analyses, suggesting that the results of this meta-analysis are
stable.
Furthermore, when we performed cancer-specific and popu-
lation-specific sensitivity analyses we found studies conducted by
Terry et al. in 2006 [34], Hashibe et al. in 2008 [14], Homann et
al. in 2006 [50] and Terry et al. in 2007 [21] were the main
origin of heterogeneity in subgroup of breast cancer, UADT
cancer, European population and mixed population, respectively.
Moreover, no single study influenced the pooled OR in each
subgroup, which indicated that results of stratified analyses were
also stable.
Publication Bias
Begg’s funnel plot and Egger’s test were performed to evaluate
the publication bias of literatures. As shown in Fig. 4, the shape of
the funnel plots seemed symmetrical in the dominant model
comparison. Then, the Egger’s test was adopted to provide
statistical evidence of funnel plot symmetry. The results still did
not show any evidence of publication bias (t =0.42, P =0.674 for
Val/Val + Ile/Val versus Ile/Ile).
Figure 2. Forest plot of cancer risk associated with the ADH1C Ile350Val polymorphism (dominant model). The squares and horizontal
lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents
the summary OR and 95% CI.
doi:10.1371/journal.pone.0037227.g002
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37227Figure 3. Forest plot of cancer risk associated with the ADH1C Ile350Val polymorphism in African and Asian populations (dominant
model). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the
variance). The diamond represents the summary OR and 95% CI.
doi:10.1371/journal.pone.0037227.g003
Figure 4. Begg’s funnel plot for publication bias test (dominant model). Each point represents a separate study for the indicated
association. Log[or], natural logarithm of OR. Horizontal line, mean effect size.
doi:10.1371/journal.pone.0037227.g004
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Genetic variation in carcinogen metabolism pathway may exert
influence on the risk of exposure-related cancer [9]. Based on the
vital role of ADH1C in ethanol oxidation to AA, numerous studies
have investigated the association of the functional ADH1C
polymorphism with types of cancers. Several studies have observed
significant association between ADH1C*1 allele and cancer risk
[21,24,38,41,43–45,48–50]. It has been widely known that
ADH1C*1 allele encode isozymes with higher catalytic activity
than the one encoded by ADH1C*2 allele and result in more
production of AA, which is a major part in ethanol-related
carcinogenesis [3] and alcoholism [53].
However, in view of the linkage disequilibrium between ADH1B
and ADH1C and the fact that the kinetic differences among
ADH1B isozymes are much more striking than those among the
ADH1C isozymes [54], some studies ascribed the association
between ADH1C polymorphism and cancer risk to the reflects of
effect of ADH1B polymorphism, especially in East Asian [18,32].
But a matter of particular note was the significant difference of
allele frequency between ADH1B and ADH1C polymorphism, that
is, the minor allele frequency (MAF) for ADH1B was 0–0.025 in
European (ADH1B*2 allele)and 0.223–0.261 in Asian (ADH1B*1
allele) populations while the MAF for ADH1C was 0.473–0.483 in
European (ADH1C*2 allele) and 0.023–0.081 in Asian (ADH1C*2
allele) populations (data from www. ncbi. nlm. nih. gov/projects/
SNP/snp_ref. cgi), which made the general attribution of ADH1C
effect to its linkage with ADH1B not reasonable. In other words, as
the two more-active alleles, ADH1B*2 and ADH1C*1 were linked
and the frequency of ADH1B*2 was too low in European, the
explanation of ADH1C effect was not well founded, especially in
European. Furthermore, there were also some studies suggesting
that the influence of ADH1C polymorphism on cancer risk was
independent of that of ADH1B in both European and Asian
populations [14,20,55,56]. Thus, the detail mechanism underlying
ADH1C polymorphism and cancer risk remains controversial and
the hypothesis that the variant of ADH1C exert an independent
influence on cancer risk by changing ethanol oxidizing capacity
[10] was better founded.
Although many studies have investigated the association
between the ADH1C polymorphism and cancer risk, the results
were inconsistent. In order to resolve this conflict, we conducted a
meta-analysis of 35 case-control studies. Because data could be
confounded by the differences between subgroups, we subsequent-
ly conducted stratified analysis by cancer type, ethnicity, source of
controls and sample size. Moreover, as Deng et al. suggested in
2001 that population admixture may potentially elevate type I
error rate of association studies and lead to inconsistent results
[52], we also conducted overall and cancer-specific analyses
excluding studies with mixed populations to confirm the effect of
this polymorphism and the impact of mixed populations.
Generally speaking, we did not find any association between
Ile350Val polymorphism and overall cancer risk. This result
indicated that individuals with the ADH1C genotype leading to
more exposure to acetaldehyde from alcohol were not at
statistically different risk of cancers. When we further performed
analyses excluding mixed populations, there were still no
associations between this polymorphism and overall cancer risk.
To a certain extent, analyses excluding mixed populations
confirmed the negative result of initial overall analyses.
In the analysis stratified by cancer type, we still did not find any
significant associations among studies of breast cancer, UADT
cancer, colorectal cancer and other cancers in any genetic model.
However, a similar meta-analysis reported recently had shown that
ADH1C*1 allele was associated with a significantly decreased risk
of pharynx cancer in dominant model [20]. Probably the
discrepancy arose because they collect data of either Arg272Gln
or Ile350Val polymorphism which were in perfect linkage
disequilibrium but may have minor differences of genotype
distribution [14,25,27] and relatively small number of studies (22
studies) they included. Interestingly, we found the effect of variant
350 Val allele on breast and other cancer risk was contrary to that
on UADT and colorectal cancer, although all the effects were not
significant. As heterogeneity among different cancers may interfere
the authenticity of result in ‘‘other cancers’’, the inverse result of
breast cancer studies called more attention. A possible explanation
is that carcinogenesis involved in different cancers is extremely
diverse. Thus, specific role of ADH1C in carcinogenic mecha-
nisms of breast cancer [27,57] as well as interaction between
special risk factors of breast cancer [58] and ADH1C gene may
contribute to the inconsistent results.
Furthermore, when we performed cancer-specific analyses
excluding studies with mixed populations, major results were
nearly the same except that a moderate increased UADT cancer
risk was founded in individuals carrying Val allele (i.e. dominant
model). However, as the lower limit of the 95% CI was 1.01 in that
comparison and the removing of some studies with relatively large
sample size (although they were with mixed populations) may also
decrease the reliability of result, we didn’t think this result was
sufficient to support the risk effect of Val allele in UADT cancer.
Therefore, studies with more samples randomly selected from one
homogeneous population are needed to further determine the
association between this variant and specific cancer risk.
Subsequently, we found an increased risk of cancer in variant
homozygote (Val/Val) carriers among Africans and in variant
allele (350 Val) carriers among Asians. Studies have indicated that
350 Val allele increases the risk for alcoholism [59], which may
lead to accumulated exposure to the highly toxic and carcinogenic
material, AA [4]. Thus, it is plausible that the presence of 350 Val
allele puts one at a greater cancer risk through susceptibility to
alcoholism. Although a few studies of Europeans suggested this
variation might be significantly associated with risk of cancer
[21,41,43,44,45,49,50], the overall difference was not significant.
We presume that the difference among ethnic groups might be a
reflection of different genetic backgrounds and environmental
context. As a number of studies attributed the effect of ADH1C
variant in East Asian to its linkage disequilibrium with ADH1B,i t
would be better for us to adjust the association found in Asian for
ADH1B polymorphism. However, among the five studies con-
ducted in Asian populations, only one [18] provided detailed data
of ADH1C genotype adjusted for ADH1B genotype. Thus, the
independent effect of ADH1C polymorphism in Asians could not
be directly estimated in the present analysis, which to some extent
was a flaw. In addition, other factors such as relatively small
sample size (204 VS. 198 of African studies and 1688 VS. 3657 of
Asian studies), selection bias and different matching criteria may
also be a possible explanation to this result.
Although hospital-based studies may have inherent selection
biases, we did not find any positive result in the stratified analysis
by population-based and hospital-based controls, indicating that
the different source of controls did not influence the association. In
addition, because studies with small sample size may have
insufficient statistical power or may have generated a fluctuated
risk estimate, we performed stratified analyses according to
subjects more than 500 in both case and control groups or not
and no significant association was detected. These results
suggested that there was no substantial impact of study sample
size on this meta-analysis.
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important in a meta-analysis, we subsequently detected source of
heterogeneity by stratifying studies according to ethnicity, cancer
type, source of control and sample size. Results showed the sources
of heterogeneity were from ethnicity and cancer type, suggesting
that certain effects of genetic variant were population and cancer
specific.
Our meta-analysis had some advantages. First, substantial
number of cases and controls were pooled from different studies,
which significantly increased statistical power of the analysis.
Second, studies included in our present meta-analysis strictly met
our selection criteria. Third, we did not detect any publication bias
indicating that the whole pooled result may be unbiased.
Except for the lacking of evaluation of independent effect of
ADH1C adjusted for ADH1B in Asian, we also had a limitation of
the present study. It has been identified that after generated from
oxidization of alcohol by ADH enzymes, AA was further oxidized
to acetate by aldehyde dehydrogenase (ALDH) enzymes and
ALDH2 contributed most to the process [60]. Thus, besides ADH,
activity of ALDH2 can also exert impact on accumulation of AA.
A functional polymorphism in ALDH2 has been identified (rs671)
to be associated with cancer risk [61,62], which lead to different
activity of ALDH2 enzyme and is prevalent in Asians [60].
Although polymorphisms of ALDH2 were not in linkage disequi-
librium with ADH, it might influence the effect of polymorphisms
of ADH1C through its impact on AA elimination. Therefore,
ALDH2 polymorphism was a potential confounder of the present
study, especially of Asian studies. Independent and combined
effect of ADH1B, ADH1C and ALDH2 variants should be evaluated
in further meta-analyses.
In conclusion, our results suggested that the ADH1C Ile350Val
polymorphism is not a candidate for susceptibility to overall
cancers. However, an increased cancer risk was observed in
populations among African and Asian, but not in European and
mixed race, which may be a reflection of ethnic differences.
Additional larger studies assessing gene-gene and gene-environ-
ment interactions should be performed to further clarify the
association of ADH genetic variants and cancer risk.
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